CUDC-101 as a dual-target inhibitor of EGFR and HDAC enhances the anti-myeloma effects of bortezomib by regulating G2/M cell cycle arrest
Journal of Zhejiang University-SCIENCE B · 2023-05 · 24 (5) · 442-454
DOI: 10.1631/jzus.b2200465 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Zhejiang University-SCIENCE B, online erschienen am 22.05.2023. Verfasst von Wen Cao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Bortezomib, ErbB Receptors, Histone Deacetylase Inhibitors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: the National Natural Science Foundation of China, the Zhejiang Key Research and Development Project.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.
- Institute of Hematology, Zhejiang University, Hangzhou 310058, China.
- School of Medicine, Zhejiang University, Hangzhou 310058, China.
- Institute of Hematology, Zhejiang University, Hangzhou 310058, China. caiz@zju.edu.cn, liyanghz@zju.edu.cn.
- Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China. caiz@zju.edu.cn.
- Institute of Hematology, Zhejiang University, Hangzhou 310058, China. caiz@zju.edu.cn.
Förderung
- the National Natural Science Foundation of China
- the Zhejiang Key Research and Development Project
Zitieren
APA
Cao, W., Yao, S., Li, A., Chen, H., Zhang, E., Cao, L., Zhang, J., Hou, Y., Dai, Z., Chen, J., Huang, X., Yang, L., & Cai, Z. (2023). CUDC-101 as a dual-target inhibitor of EGFR and HDAC enhances the anti-myeloma effects of bortezomib by regulating G2/M cell cycle arrest. Journal of Zhejiang University-SCIENCE B, 24(5), 442-454. https://doi.org/10.1631/jzus.b2200465
Vancouver
Cao W, Yao S, Li A, Chen H, Zhang E, Cao L, et al. CUDC-101 as a dual-target inhibitor of EGFR and HDAC enhances the anti-myeloma effects of bortezomib by regulating G2/M cell cycle arrest. Journal of Zhejiang University-SCIENCE B. 2023;24(5):442-454. doi:10.1631/jzus.b2200465
BibTeX
@article{Cao2023,
author = {Cao, Wen and Yao, Shunnan and Li, Anqi and Chen, Haoguang and Zhang, Enfan and Cao, Liqin and Zhang, Jinna and Hou, Yifan and Dai, Zhenfeng and Chen, Jing and Huang, Xi and Yang, Li and Cai, Zhen},
title = {CUDC-101 as a dual-target inhibitor of EGFR and HDAC enhances the anti-myeloma effects of bortezomib by regulating G2/M cell cycle arrest},
journal = {Journal of Zhejiang University-SCIENCE B},
year = {2023},
volume = {24},
number = {5},
pages = {442--454},
doi = {10.1631/jzus.b2200465}
}
EUVIMED